Download Free Biotechnology In The Time Of Covid 19 Book in PDF and EPUB Free Download. You can read online Biotechnology In The Time Of Covid 19 and write the review.

47 leaders from across the biotechnology industry tell their stories of battling the global scourge of COVID-19. Pandemics have killed at least a half billion people over the past two millennia. But in the age of biotechnology, humanity is no longer defenseless. The biotechnology industry is a diverse community of scientists, doctors, patients, entrepreneurs, investors, bankers, analysts and reporters, all committed to treating and curing disease. Over the past forty years, it has produced medical advances at an electrifying rate. As the COVID-19 pandemic emerged, hundreds of companies quickly pivoted to combating the virus. The contributors to this book offer inside views of this seminal industry, with historical and personal perspectives, lessons learned, and looks into the future. Diverse as these leaders are, they are united by their conviction that science and medicine will light humanity’s way to greater health and longevity.
A global, timely calling card for the biotechnology industry, and their efforts going forward during the COVID-19 pandemic. A collection of diverse viewpoints from over 40 thought leaders in the biotech industry.
This book provides an inclusive and comprehensive discussion of the transmission, science, biology, genome sequencing, diagnostics, and therapeutics of COVID-19. It also discusses public and government health measures and the roles of media as well as the impact of society on the ongoing efforts to combat the global pandemic. It addresses almost every topic that has been studied so far in the research on SARS-CoV-2 to gain insights into the fundamentals of the disease and mitigation strategies. This volume is a useful resource for virologists, epidemiologists, biologists, medical professionals, public health and government professionals, and all global citizens who have endured and battled against the pandemic.
Biomedical Innovations to Combat COVID-19 provides an updated overview on the development of vaccines, antiviral drugs and nanomaterials, and diagnostic methods for the fight against COVID-19. Perspectives on such technologies are identified, discussed, and enriched with figures for easy understanding and applicability. Furthermore, it contains basic aspects of virology, immunology, and antiviral drugs that are needed to fully appreciate these innovations. This book is split into four sections: introduction, presenting basic virologic and epidemiological aspects of COVID-19; vaccines against COVID-19, discussing their different types and applications used to develop them; diagnostic approaches for SARS-CoV-2, encompassing advanced sensing and microfluidic-based biosensors; and drug development and delivery, where antivirals based on nanomaterials or drugs are presented. It is a valuable source for virologists, biotechnologists, and members of biomedical field interested in learning more about how novel technologies can be applied to fasten the eradication of the COVID-19 and similar pandemics. Presents updated literature coverage summarizing the most relevant information on COVID-19 Written by experts from diverse scientific domains in order to provide readers with a thorough view on the subject Encompasses tables, figures and information trees especially developed for the book in order to condense and highlight key points for quick reference
Winners of the Paul Ehrlich Prize The dramatic story of the married scientists who founded BioNTech and developed the first vaccine against COVID-19. Nobody thought it was possible. In mid-January 2020, Ugur Sahin told Özlem Türeci, his wife and decades-long research partner, that a vaccine against what would soon be known as COVID-19 could be developed and safely injected into the arms of millions before the end of the year. His confidence was built upon almost thirty years of research. While working to revolutionize the way that cancerous tumors are treated, the couple had explored a volatile and overlooked molecule called messenger RNA; they believed it could be harnessed to redirect the immune system's forces against any number of diseases. As the founders of BioNTech, they faced widespread skepticism from the scientific community at first; but by the time Sars-Cov-2 was discovered in Wuhan, China, BioNTech was prepared to deploy cutting edge technology and create the world’s first clinically approved inoculation for the coronavirus. The Vaccine draws back the curtain on one of the most important medical breakthroughs of our age; it will reveal how Doctors Sahin and Türeci were able to develop twenty vaccine candidates within weeks, convince Big Pharma to support their ambitious project, navigate political interference from the Trump administration and the European Union, and provide more than three billion doses of the Pfizer/BioNTech vaccine to countries around the world in record time. Written by Joe Miller—the Financial Times’ Frankfurt correspondent who covered BioNTech’s COVID-19 project in real time—with contributions from Sahin and Türeci, as well as interviews with more than sixty scientists, politicians, public health officials, and BioNTech staff, the book covers key events throughout the extraordinary year, as well as exploring the scientific, economic, and personal background of each medical innovation. Crafted to be both completely accessible to the average reader and filled with details that will fascinate seasoned microbiologists, The Vaccine explains the science behind the breakthrough, at a time when public confidence in vaccine safety and efficacy is crucial to bringing an end to this pandemic.
Looking for information about the key elements in the ongoing war against the COVID-19 pandemic? Confused and upset by all the conflicting information from many sources? This book from genomics industry expert Dale Yuzuki breaks down diagnostics, therapeutics and vaccines from an insider's perspective written for the non-expert. You will get the needed context to put all the biomedical advances continually reported on into perspective, and feel reassured that all the activity that is going on "behind the scenes" will finally put an end to the pandemic that is upending the lives of everyone. Curious to see how this war will ultimately end?
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
"An inspiring and informative page-turner." –Walter Isaacson Longlisted for the FT/McKinsey Business Book of the Year Award The authoritative account of the race to produce the vaccines that are saving us all, from the #1 New York Times bestselling author of The Man Who Solved the Market Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world’s biggest drug and vaccine makers were slow to react or couldn’t muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life’s work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. A #1 New York Times bestselling author and award-winning Wall Street Journal investigative journalist lauded for his “bravura storytelling” (Gary Shteyngart) and “first-rate” reporting (The New York Times), Zuckerman takes us inside the top-secret laboratories, corporate clashes, and high-stakes government negotiations that led to effective shots. Deeply reported and endlessly gripping, this is a dazzling, blow-by-blow chronicle of the most consequential scientific breakthrough of our time. It’s a story of courage, genius, and heroism. It’s also a tale of heated rivalries, unbridled ambitions, crippling insecurities, and unexpected drama. A Shot to Save the World is the story of how science saved the world.
This open access book is a collection of research papers on COVID-19 by Germán Velásquez from 2020 and early 2021 that help to answer the question: How can an agency like the World Health Organization (WHO) be given a stronger voice to exercise authority and leadership? The considerable health, economic and social challenges that the world faced at the beginning of 2020 with COVID-19 continued and worsened in many parts of the world in the second-half of 2020 and into 2021. Many of these countries and nations wanted to explore COVID-19 on their own, sometimes without listening to the main international health bodies such as WHO, an agency of the United Nations system with long-standing experience and vast knowledge at the global level and of which all countries in the world are members. In this single volume, the chapters present the progress of thinking and debate — particularly in relation to drugs and vaccines — that would enable a response to the COVID-19 pandemic or to subsequent crises that may arise. Among the topics covered: COVID-19 Vaccines: Between Ethics, Health and Economics Medicines and Intellectual Property: 10 Years of the WHO Global Strategy Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock Intellectual Property and Access to Medicines and Vaccines The World Health Organization Reforms in the Time of COVID-19 Vaccines, Medicines and COVID-19: How Can WHO Be Given a Stronger Voice? is essential reading for negotiators from the 194 member countries of the World Health Organization (WHO); World Trade Organization (WTO) and World Intellectual Property Organization (WIPO) staff participating in these negotiations; academics and students of public health, medicine, health sciences, law, sociology and political science; and intergovernmental organizations and non-governmental organizations that follow the issue of access to treatments and vaccines for COVID-19.
Due to the COVID-19 pandemic, interest in COVID-19 vaccines and treatments has grown. In addition, awareness of the importance of healthcare and disease prevention has risen, thus demand for related goods has also increased. There are movements to preempt emerging industries, such as pharmaceuticals, healthcare, and telemedicine, around the world. Recently, Korea selected the biotech industry as one of the so-called “BIG3” future industries primed to lead national innovative growth, along with the future mobility and non-memory semiconductors industries. The BIG3 industries are targets of four trillion KRW in government investment, which is an increase of 900 billion KRW from the previous year. Of those investments, about 1.7 trillion KRW will be allocated to the biotech and healthcare sectors. Other major countries such as the US, Japan, EU, and Israel are expanding R&D investments in those sectors to improve industrial competencies and to respond to COVID-19.